Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
<p><strong>Background</strong></p> <p>The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion protocol at 6 mo posttransplant to promot...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wolters Kluwer
2024
|